Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05227339 · ClinicalTrials.gov registry record · Phase 2
RAE (Realize, Analyze, Engage)
A Phase 2 study of Substance Use Disorders and Treatment Adherence and Compliance, sponsored by ContinueYou.
- Completed
- Registry status
- Phase 2
- Development phase
- 209
- Enrollment target
- 1
- Study location
NCT05227339: Completed Phase 2 study of Substance Use Disorders and Treatment Adherence and Compliance, sponsored by ContinueYou.
NCT05227339 is a Phase 2 study of Substance Use Disorders and Treatment Adherence and Compliance that has completed, run by ContinueYou. The registered enrollment target is 209 participants, below the 498-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05227339, a Phase 2 study of Substance Use Disorders and Treatment Adherence and Compliance, has completed, sponsored by ContinueYou.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 209 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study will evaluate the detection of digital biomarkers of stress, and drug craving in a population of individuals undergoing treatment for substance use disorder
Primary Outcome
Relapse to use of substance use defined as 1) self-reported use, 2) positive urine drug screen (from treatment program) or 3) provider report of confirmed relapse (Only applies to substances for which subject is receiving treatment)
Conditions Studied
Interventions
- DEVICE RAE
Study Locations (1)
Massachusetts
- University of Massachusetts Chan Medical School - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2022-02-22 |
| Est. Completion | 2024-04-01 |
| Phase | Phase 2 |
What the finished NCT05227339 record still lists
NCT05227339 is an interventional study that assigns participants to a tested intervention. The registered 209 participants enrollment target is mid-sized for trials with a published cap, below the 498-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (58% lower).
The record links to 2 conditions, with Substance Use Disorders appearing as the primary indexed condition, and to 1 intervention - of which RAE is the first listed.
NCT05227339 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05227339 about?
NCT05227339 is a clinical study titled "RAE (Realize, Analyze, Engage)". The proposed study will evaluate the detection of digital biomarkers of stress, and drug craving in a population of individuals undergoing treatment for substance use disorder
What is the current status of trial NCT05227339?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 209 participants. The study started on 2022-02-22. Estimated completion is 2024-04-01.
What conditions does trial NCT05227339 study?
This clinical trial studies the following conditions: Substance Use Disorders, Treatment Adherence and Compliance.
What interventions are being tested in trial NCT05227339?
The interventions under investigation include: RAE (DEVICE).
Who is sponsoring clinical trial NCT05227339?
This trial is sponsored by ContinueYou, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05227339 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Use Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05227339's enrollment target sits among peer trials
209 31st of 93 higher than 63 of 93 other Substance Use Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance Use Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Ketamine for Methamphetamine Use Disorder
RECRUITING · Phase 2
-
Supporting Treatment Access and Recovery Through Linkage and Support
RECRUITING · NA
-
Development OF A Novel Peer Recovery Supporter Training Platform
RECRUITING · NA
-
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
RECRUITING · NA
-
Testing Strategies to Improve Substance Misuse Prevention Research Use in State Policy Contexts
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04742634 · 209 participants · Phase 1
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
- NCT07214688 · 209 participants · Phase 2
Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI